Format

Send to

Choose Destination
Invest New Drugs. 2014 Oct;32(5):1048-52. doi: 10.1007/s10637-014-0063-z. Epub 2014 Jan 18.

Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature.

Author information

1
Division of Clinical Sciences, St George's University of London, Cranmer Terrace, London, SW17 0RE, UK, dalgleis@sgul.ac.uk.

Abstract

A role for CD20 antibodies in treating prostate cancer has not yet been established. We report a case of advanced prostate cancer presenting with generalized lymphadenopathy that expressed CCR7 and CD20. CCR7 expression in prostate cancer has been previously reported only once; the expression of CD20 has not been reported before. Rituximab therapy was initiated in this case and resulted in a significant biochemical response. This unique metastatic and biochemical pattern may signify a distinct subtype of prostate cancer that may be amenable to treatment with anti-CD20 antibodies.

PMID:
24442368
DOI:
10.1007/s10637-014-0063-z
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center